Latest news with #LeicaBiosystems
Yahoo
31-05-2025
- Business
- Yahoo
Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests
Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the development and commercialization of advanced diagnostic tools aimed at expanding precision medicine. Leveraging DHR's newly launched Centers for Enabling Precision Medicine, the collaboration will focus on creating AI-powered diagnostics to help clinicians better identify which patients are most likely to benefit from targeted therapies, such as next-generation antibody-drug conjugates. A handshake between two men in the lobby of a modern office building, signifying the formation of a Master Limited Partnership. The partnership's first initiative will utilize technologies from Leica Biosystems, a Danaher Corporation (NYSE:DHR) subsidiary renowned for its digital pathology solutions. The initial emphasis will be on digital and computational pathology products and AI-assisted algorithms, aiming to improve diagnostic accuracy and patient selection for precision treatments. Leica Biosystems is also committed to advancing interoperability in clinical workflows through open-access DICOM standards. Danaher Corporation (NYSE:DHR) Executive Vice President Julie Sawyer Montgomery highlighted the goal of increasing access to precision medicines so that no patients are left behind, while AstraZeneca PLC (NASDAQ:AZN)'s Susan Galbraith underscored the critical role of AI-based diagnostics in matching patients with the most effective therapies. Both companies view this collaboration as a significant step toward global digital transformation in pathology and a milestone in delivering personalized healthcare solutions worldwide While we acknowledge the potential of DHR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DHR and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-05-2025
- Business
- Yahoo
Danaher and AstraZeneca to develop diagnostic tools and tests
Danaher Corporation has announced a collaboration with AstraZeneca for diagnostic tools and tests development and commercialisation, which will aid clinicians in identifying individuals who may benefit from precision medicines. This collaboration will leverage the resources of the newly opened Danaher Centers for Enabling Precision Medicine to streamline the development process. The first product to be developed through this alliance will utilise technologies from Danaher's subsidiary, Leica Biosystems. The initial focus will be on creating computational and digital pathology products, as well as AI-assisted algorithms to improve diagnosis and identify patients likely to respond to targeted therapies. Leica is said to have developed digital pathology solutions and is scaling these technologies for clinical use across its global laboratory network. To expedite this, Leica has committed to the open-access Digital Imaging and Communications in Medicine (DICOM) standard, promoting interoperability and workflow connectivity. AstraZeneca oncology haematology research and development (R&D) executive vice-president Susan Galbraith said: "The transformative potential of next-wave precision medicines such as antibody-drug conjugates will depend on our ability to identify the patients most likely to benefit from them. "Our partnership with Danaher and Leica Biosystems underscores our commitment to pioneering AI-based diagnostics, which can improve patient selection, and our belief that collaboration is a critical accelerant for such progress." Danaher's knowledge in science and technology is pivotal for enabling quick diagnoses and decreasing the time and expenses associated with discovering, developing, and delivering the therapies. In August 2023, Danaher signed an agreement to acquire all outstanding shares of UK-based protein consumables supplier Abcam in a transaction valued at $5.7bn. "Danaher and AstraZeneca to develop diagnostic tools and tests" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid diagnostics research, development and commercialization Danaher, through its Centers for Enabling Precision Medicine, will provide support in all aspects of the development cycle across diagnostic modalities WASHINGTON, May 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, announced today the launch of a partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize novel diagnostic tools and tests intended to help clinicians better determine which patients would most benefit from precision medicine treatments. "Precision medicines are more targeted than standard therapies and thus require precision diagnostics to determine which patients are most likely to benefit," said Julie Sawyer Montgomery, Danaher Executive Vice President. "We are excited to work with AstraZeneca on the goal of creating novel tests to increase access to precision medicines, helping ensure that no patients are left behind." This partnership will utilize the newly opened Danaher Centers for Enabling Precision Medicine to support a more streamlined, end-to-end development process. The first product intended to be developed through this partnership will leverage technologies from Leica Biosystems, one of Danaher's subsidiaries. The initial focus will be on digital and computational pathology products and AI-assisted algorithms, to help clinicians better diagnose patients by identifying those who are most likely to benefit from targeted therapies. "The transformative potential of next-wave precision medicines such as antibody-drug conjugates will depend on our ability to identify the patients most likely to benefit from them," said Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca. "Our partnership with Danaher and Leica Biosystems underscores our commitment to pioneering AI-based diagnostics which can improve patient selection, and our belief that collaboration is a critical accelerant for such progress." Leica Biosystems has developed leading digital pathology solutions and intends to scale these for use in clinical settings across its footprint of laboratories around the world. To accelerate this digital transformation, the company recently shared its commitment to an open-access Digital Imaging and Communications in Medicine (DICOM) standard, encouraging interoperability for enhanced workflow connectivity. "At Leica Biosystems, we've been driving the new era of digital pathology, where assays that used to be analyzed by the human eye are now also analyzed by digital tools, helping to improve diagnostic accuracy and therapeutic guidance," said Gustavo Perez-Fernandez, President of Leica Biosystems. "With our global footprint and leading digital pathology platform, we expect to be able to deploy the tests developed with AstraZeneca to patients worldwide, which could significantly advance precision medicine and improve outcomes for patients on a global scale." ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at FORWARD-LOOKING STATEMENTS Statements in this release that are not strictly historical, including any statements of Danaher or any of its direct or indirect subsidiaries regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of tariffs and related actions recently implemented by the U.S. and other countries, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the healthcare industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the healthcare industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory changes or uncertainty and military conflicts), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2024 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the first quarter of 2025. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise. View original content: SOURCE Danaher Corporation
